Clinical trial
Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat…
NCT00291616 · Seoul National University Hospital, Other · Completed
Key facts
| NCT number | NCT00291616 |
|---|---|
| Title | Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B |
| Official title | A Multicenter, Randomized, Controlled Trial of Combination Therapy for HBeAg Positive Chronic Hepatitis B: Comparing Thymosin Alpha 1 and Pegylated Interferon-alpha2a With Pegylated Interferon-alpha2a Alone. |
| Lead sponsor | Seoul National University Hospital, Other |
| Collaborators | Roche Pharma AG Industry SciClone Pharmaceuticals |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | Pegylated Interferon-alpha2a, Thymosin alpha1 & Pegylated Interferon-alpha2a |
| Enrollment | 52 |
| Start date | Dec 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Feb 14, 2006 |
| Last update posted | Jul 21, 2011 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: